Lifecore (LFCR) Biomedical announced that it has signed a CDMO master services agreement with a new large global pharmaceutical customer. Under the terms of the agreement, Lifecore will conduct development services and tech transfer for an injectable pharmaceutical product with the intent to transfer commercial supply from facilities overseas to Lifecore’s facilities. Once commercial transfer activities are complete and all regulatory requirements are satisfied, Lifecore expects to become the commercial supplier of choice for the product. This is the second agreement that Lifecore has signed in the past three months with a multinational pharmaceutical company. Based on the current commercial revenues for this latest program, the new partner has the potential to become one of Lifecore’s top five commercial customers.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Cautious Hold Rating on Lifecore Biomedical Amid Operational Progress and Financial Risks
- Optimistic Outlook for Lifecore Biomedical: Strategic Growth and Financial Stability
- Lifecore Biomedical Reports Strong Revenue Growth
- Lifecore backs transition period revenue view $74M-$76M
- Lifecore reports Q3 EPS (29c), consensus (31c)